Navigation Links
Auxilium Pharmaceuticals to Announce Second Quarter 2011 Results and Conduct Conference Call on Monday, August 1, 2011
Date:7/18/2011

for the treatment of adult Dupuytren's contracture patients with a palpable cord and Testim® 1%, a testosterone gel, for the topical treatment of hypogonadism in the U.S. Pfizer Inc. has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia and Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A. markets Testim in the EU and Paladin Labs Inc. markets Testim in Canada. Auxilium has two projects in clinical development. XIAFLEX is in phase III of development for the treatment of Peyronie's disease and is in phase II of development for treatment of Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium also has rights to pursue additional indications for XIAFLEX. For additional information, visit http://www.auxilium.com.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 This release contains "forward-looking-statements" within the meaning of The Private Securities Litigation Reform Act of 1995, including statements regarding the Company's intention to announce the second quarter 2011 results; and the potential for XIAFLEX to be used in multiple indications.  

Forward-looking statements often address Auxilium's expected future financial position or business strategy and plans and objectives of management for future operations. Forward-looking statements provide Auxilium's current expectations or forecasts of future events. Auxilium's performance and financial results could differ materially from those reflected in these forward-looking statements due to various risks and uncertainties.

A more detailed list and description of the risks and uncertainties that Auxilium faces may be found under the heading "Risk Factors" in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2010 and Form 10-Q for the qua
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytrens Contracture
3. BioSpecifics Technologies Corp. Announces Auxilium XIAFLEX® Update
4. Auxilium Pharmaceuticals, Inc. Announces Initiation of XIAFLEX® Phase III Studies for Peyronies Disease
5. Auxilium Pharmaceuticals, Inc. Announces Issuance of Patent for Clostridial Collagenase
6. Auxilium Pharmaceuticals to Present at the 2010 Annual Credit Suisse Healthcare Conference
7. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
8. Auxilium Pharmaceuticals to Present at the 2011 Citi Annual Global Healthcare Conference
9. Auxilium Pharmaceuticals to Present at the Cowen and Company 31st Annual Health Care Conference
10. Auxilium Pharmaceuticals, Inc. Completes Enrollment of XIAFLEX® Phase III Double-Blind Studies for Peyronies Disease
11. Auxilium Pharmaceuticals, Inc. and Asahi Kasei Pharma Corporation Enter Agreement to Develop, Commercialize and Supply XIAFLEX® In Japan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Dignity Health St. Mary,s Medical Center ... With The Guidelines®-Stroke Silver-Plus Quality Achievement Award for ... American Heart Association/American Stroke Association for the treatment ... cause of death and a leading cause of ... , according to the American Heart Association/American ...
(Date:7/28/2014)... , July 28, 2014 Reportbuyer.com has ... Global Bone Densitometers Market 2014-2018 ... bone densitometry scan is a special type of X-ray ... bone. It is used primarily to detect osteopenia or ... and the risk of fractures is high. The purpose ...
(Date:7/28/2014)... Reportlinker.com announces that a new market ... Portugal Pharmaceuticals and Healthcare Report Q3 ... Includes 3 FREE quarterly updates ... last quarter has led us to revise our ... previously, BMI expects Portugal,s ...
Breaking Medicine Technology:Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3Global Bone Densitometers Market 2014-2018 2Global Bone Densitometers Market 2014-2018 3Global Bone Densitometers Market 2014-2018 4Global Bone Densitometers Market 2014-2018 5Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4
... (Nasdaq: VICL ),today is presenting expanded clinical ... Vaxfectin(R) adjuvant may be broadly,applicable in DNA- and ... P. Rolland, Pharm.D., Ph.D., Vical,s,Senior Vice President of ... 8, at the World Vaccine Congress (Lyon, France ...
... Texas, Oct. 7 The Texas Cardiac Arrhythmia,Institute ... selected as one of,only a few sites in ... for a new device to treat persistent atrial ... specializing in heart,rhythm disorders, is a partnership between ...
Cached Medicine Technology:Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 2Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 3Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 4Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months 5Texas Cardiac Arrhythmia Institute at St. David's Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation 2
(Date:7/28/2014)... gluttons. We have long known that they monopolize large ... some tumor cells are also characterized by a series ... in an ordered set. Researchers are calling this behavior ... EPFL, Etienne Meylan,s research team was able to demonstrate ... mesenchymal behavior result from the same mechanism, at ...
(Date:7/28/2014)... July 29, 2014 The ... Situ Hybridization, Digital pathology & Workflow, Special ... Prostate Cancer, Non Small Cell Lung Cancer ... (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research ... Americas, Europe, BRIC, Japan & RoW) - ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 A lush green ... playtime during the summer. However, the summer heat, lack of ... to become brown, weak and unhealthy. The Grounds Guys recommends ... Grow, Mow a lawn once a week and set the ... normal. This protects the grass roots from heat and allows ...
(Date:7/28/2014)... UHY LLP, a member of the ... UHY International Business – Issue 29. This bi-annual publication ... most current business challenges and key issues faced by ... the following topics:, , Key industry ... over the next five years? Where are growth opportunities ...
(Date:7/28/2014)... Dawn Echols’ professional background spans success in ... experience has honed her people skills and led ... counseling ( http://dawningphoenix.com ) work includes private practice, ... domestic violence. , As owner and executive ... individuals and groups for a variety of disorders. ...
Breaking Medicine News(10 mins):Health News:Cancer: Tumors absorb sugar for mobility 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 2Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 3Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 4Health News:Advanced Cancer Diagnostics Market Worth $3,924.01 Million by 2018 - New Report by MarketsandMarkets 5Health News:Nurturing Lawns in the Summer Heat: The Grounds Guys® Offers Tips on Caring for Lawns This Summer 2Health News:Uhy International Business Issue 29 Now Available 2Health News:Uhy International Business Issue 29 Now Available 3Health News:Dawn M. Echols, M.S., LPC of Dawning Phoenix Speaks at Newly Formed Task Force 2
... have uncovered evidence that the abnormal editing of gene messages ... the development of lupus. Scientists hope the finding will lead ... therapy and possibly a new way to treat the disease. ... an enzyme that edits and modifies the messages of genes ...
... At the "World Aquaculture,2008", held on May ... from,the University of Strathclyde, Scotland, United Kingdom, was ... innovative statistical and,epidemiological research methods in sea-lice treatments ... an excellent example of commitment to,the advancement of ...
... money and time spent in intensive care units, researcher ... tubes coated with silver dramatically reduce infections from highly ... breathe through a tube placed through their trachea and ... developing what is called ventilator-associated pneumonia. , "Ventilator-associated pneumonia ...
... Murad, Inc. announced today,the appointment of Fernando Braga, ... for Latin America. In this position, Braga will,develop ... in key,areas, identify prospective partners and create new ... http://www.newscom.com/cgi-bin/prnh/20080519/LAM066 ), "Fernando joins the Murad family ...
... AUSTIN, TexasAging brings a sense of peace and calm, according ... The University of Texas at Austin. Starting at about age ... their younger counterparts. , Catherine Ross and John Mirowsky, professors ... Balance of Emotions in the May 19 issue of Social ...
... Anthem Members in six California, counties - Los Angeles, Alameda, Contra ... of Costs Associated with Medical ... Procedures, ... today the expansion of its industry-leading,transparency initiative into California. Now, approximately 1.8 ...
Cached Medicine News:Health News:Abnormal 'editing' of gene messages may be a cause of lupus 2Health News:Prof. Dr. George Gettinby Honored With Dieter Lutticken Award 2Health News:Prof. Dr. George Gettinby Honored With Dieter Lutticken Award 3Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 2Health News:Silver-Coated Endotracheal Tubes Cut Down on Infections 3Health News:Murad, Inc., Appoints Fernando Braga, Jr. as Director of International Business for Latin America 2Health News:With age comes a sense of peace and calm, population research center study shows 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 2Health News:Anthem Blue Cross Introduces Industry's Most Comprehensive Transparency Initiative to California 3
TeleRehab Advantage is a monitoring system that automates the generation of outcomes data. Patient information and session information is automatically transferred from the monitoring program to Outc...
... Clearly, the ISI Lexan ... versatile surgical table for lower ... orthopaedic, head and neck, and ... optional traction package gives you ...
MagaCell-Streptavidin is a streptavidin coupled to magnetizable cellulose/iron oxide particles...
Streptavidin A-Beads are polydisperse 1.8 m paramagnetic particles covalently coupled with streptavidin. The paramagnetic particles remain in solution over extended periods of time. Mixing is require...
Medicine Products: